Author Archive: Lila Feisee

Lila is the Vice President for Global Intellectual Property Policy at BIO and has been with the organization since June of 2000. Lila is responsible for domestic and international IP and technology transfer issues affecting the biotechnology industry. Before joining BIO, she worked for 10 years at the United States Patent and Trademark Office (PTO), first as an examiner and later in management and policy development. Her primary areas of expertise in both examination and management are protein engineering, therapeutics, and assays. She also worked at the National Institutes of Health in the National Cancer Institute, Laboratory of Genetics where she isolated and characterized viral and human oncogenes. Lila received her bachelor’s of science degree in biology from the University of Virginia and her post graduate degree in genetics from the George Washington University School of Medicine.

Latest Posts

Bayh-Dole Can Bring Money for Research and Education

There is a movement out there among scientists who would like to see patents lifted, and have everything freely available. Let’s think about that for a minute. Would that really be a good idea? There is an article in the February 2 edition of the University of California at Los Angeles Daily Bruin, titled, “Inventions provide money, jobs for UC.” Excellent point — if there is intellectual property, there must be money involved and it Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , ,

Help the United States Patent and Trademark Office (USPTO)

Recently our President & CEO, Jim Greenwood sent a letter to President Obama, congratulating him on his historic election, and providing him with a few suggestions as to how to improve things at the USPTO. For those of you who aren’t super-familiar with the USPTO, let me just say that they have been charged with the processing of patent applications and granting patents. Patents, as our sixteenth president, Abraham Lincoln very eloquently said, “add the Read More >

Patently BIOtech  |  5 Comments  |  Email This Post
Tags: , , , ,

Is the FTC well-suited to take on IP/Patent policy?

On December 5, 2008 the Federal Trade Commission held the first in a series of hearings entitled: The Evolving IP Marketplace. According to the FTC, the hearings are intended to examine changes in intellectual property law and patent-related business models since the FTC issued its October 2003 report, entitled To Promote Innovation: The Proper Balance of Competition and Patent Law and Policy A Report by the Federal Trade Commission. December 5th’s hearing featured CAFC Chief Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,